We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Hemopurifier Removes Viruses from Blood by Filtration

By Labmedica staff writers
Posted on 15 Jul 2008
A hemopurifier has been developed to filter out viruses and toxins from blood before they attack organs. More...


The method is very similar to dialysis, and can be used to help patients with human immunodeficiency virus (HIV), hepatitis C (HIC), measles, mumps, and influenza. It can also begin working before doctors identify the cause of the illness. Designed by infectious disease experts, the machine uses thin fibers to capture and remove viruses from the blood it filters. The process requires the drawing of blood through an artery, which is sent through a tube into the machine.

The toxin filters work like a colander, allowing small viruses through but not large red and white blood cells. The filter, which is made from a biocompatible plastic called polysulfone, is coated with special plant-derived antibodies that hold fast to the pathogens, ensuring that they do not reenter the bloodstream. Purified blood travels back into the body through a second tube inserted into another artery. The human body typically contains about five liters of blood. The entire quantity can flow through the Hemopurifier in about 12 minutes. The process is repeated until all the toxins are removed--usually within a few hours

The Hemopurifier resembles a shrunken dialysis cartridge, the device that purifies the blood of patients whose kidneys have failed. Both use a filter to remove toxins from blood. But unlike traditional dialysis, the hemopurifier also includes plant-derived antibodies, such as cyanovirin, that bind to a variety of viruses and eliminates them from the bloodstream. The plant solution can be modified to weed out even genetically engineered organisms.

Aethlon Medical (San Diego, CA, USA) manufactured two versions of the hemopurifier device. One, a foot long and an inch wide, is designed for use in hospitals; the other, the size of a large pen, is meant for use in the field. Both types attach to a pump. The portable version could work without the pump, using the patient's heart as the engine to force blood through the filter.

Aethlon recently shipped several hemopurifiers to the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) for cell culture tests on human blood infected with Ebola. Meanwhile, the company has already completed its own tests in animals. Although promising, the Hemopurifier still has a few big hurdles to clear, the biggest of which is successful testing in humans. Aethlon is completing safety trials in India and hopes to begin clinical tests in the United States by the end of 2008.


Related Links:
Aethlon Medical
U.S. Centers for Disease Control and Prevention

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.